We are live on ! Find out more
ZIVOW

Zivo Bioscience, Inc. Warrants

Delisted

ZIVOW was delisted on the 24th of November, 2023.

5 hedge funds and large institutions have $66K invested in Zivo Bioscience, Inc. Warrants in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 55 (0)

26% less capital invested

Capital invested by funds: $89K → $66K (-$23K)

Holders
5
Holders Change
Holders Change %
0%
% of All Funds
0.08%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
2
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change
Change in
Stake
AC
1
Ayrton Capital
Connecticut
$31K
WAM
2
Warberg Asset Management
Illinois
$17K +$5.31K +6,739 +35%
CH
3
CVI Holdings
Delaware
$10K
VCA
4
Verdence Capital Advisors
Maryland
$6K
UBS Group
5
UBS Group
Switzerland
$2K +$1.48K +1,873 +131%

ZIVOW Hedge Fund Activity: Q1 2022 in Review

5 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Zivo Bioscience, Inc. Warrants (ZIVOW) for Q1 2022, worth a combined $66K — down 26% from $89K a quarter earlier.

Fund positioning in ZIVOW was balanced in Q1 2022: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 0 trimmed.

The largest buyer was Warberg Asset Management, adding an estimated $5.31K.

  • 5 institutional investors held Zivo Bioscience, Inc. Warrants (ZIVOW) as of Q1 2022, unchanged from Q4 2021.
  • Funds reported $66K of Zivo Bioscience, Inc. Warrants stock for Q1 2022, down 26% quarter-over-quarter.
  • 0 funds opened new Zivo Bioscience, Inc. Warrants positions in Q1 2022 and 0 closed out.
  • The largest Zivo Bioscience, Inc. Warrants buyer in Q1 2022 was Warberg Asset Management, an estimated $5.31K added.

Based on aggregated 13F filings for Q1 2022.